CHE Chemed Corp

Chemed Corporation (NYSE:CHE) has experienced a 3.5% stock price decline over the past three months, but its financial fundamentals appear sound. The company's Return on Equity (ROE) stands at an impressive 26%, significantly higher than the industry average. Despite strong profitability and a low payout ratio suggesting considerable reinvestment, Chemed's earnings growth has been flat over the last five years, raising questions about factors limiting its expansion.

This article from Stock Traders Daily analyzes Chemed Corp (NYSE: CHE), noting stable neutral readings in shorter horizons that could signal an easing of a long-term weak bias. It highlights an exceptional 36.6:1 risk-reward setup targeting a 10.6% gain versus a 0.3% risk. The report also provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.

Riverbridge Partners LLC reduced its stake in Chemed Corporation (NYSE:CHE) by 8.1% in Q3 2025, selling 5,029 shares and now holding 56,975 shares valued at approximately $25.51 million. Despite Riverbridge's reduction, other institutional investors like Norges Bank and AQR Capital Management significantly increased their holdings, bringing overall institutional ownership to about 95.85%. Chemed recently missed its quarterly EPS and slightly missed revenue expectations but provided FY2025 guidance above analyst averages and declared a $0.60 quarterly dividend.

Chemed Corporation (CHE) shows growth potential, particularly in its VITAS hospice care segment due to increased admissions and strategic initiatives. The Roto-Rooter segment also demonstrates resilience, achieving modest revenue growth despite market challenges. However, the company faces risks from macroeconomic headwinds, such as inflation and tariffs, which could impact profitability, and competition in both its operating segments.

This article provides an in-depth analysis of Chemed Corp (NYSE: CHE) based on AI-generated signals, highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels. The analysis identifies an exceptional 38.1:1 risk-reward setup targeting an 11.1% gain versus 0.3% risk.

Chemed Corporation (NYSE:CHE) has received a consensus "Moderate Buy" rating from six analysts, with an average 12-month price target of $574.25. Despite narrowly missing quarterly earnings and revenue estimates, the company issued optimistic FY2025 EPS guidance. Insider selling by the CEO and significant institutional ownership were also noted.